Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenobamate in drug-resistant focal epilepsy
ChiCTR2600135371Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cenobamate in epilepsy and Focal Onset Epilepsy, sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Change in seizure frequency from baseline. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
cenobamate
03
Conditions
epilepsyFocal Onset Epilepsy
Beyond the preview
Go deeper on ChiCTR2600135371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135371.